Unique ID issued by UMIN | UMIN000002183 |
---|---|
Receipt number | R000002679 |
Scientific Title | A Phase I/II study of combination of TS-1, CDDP plus PTX in patients with advanced/recurrent gastric cancer (OGSG 0703) |
Date of disclosure of the study information | 2009/07/10 |
Last modified on | 2013/01/10 20:35:56 |
A Phase I/II study of combination of TS-1, CDDP plus PTX in patients with advanced/recurrent gastric cancer (OGSG 0703)
A Phase I/II study of combination of TS-1, CDDP plus PTX in patients with advanced/recurrent gastric cancer (OGSG 0703)
A Phase I/II study of combination of TS-1, CDDP plus PTX in patients with advanced/recurrent gastric cancer (OGSG 0703)
A Phase I/II study of combination of TS-1, CDDP plus PTX in patients with advanced/recurrent gastric cancer (OGSG 0703)
Japan |
advanced/recurrent gastric cancer
Gastroenterology | Hematology and clinical oncology | Gastrointestinal surgery |
Malignancy
NO
A regimen of TS-1+CDDP plus PTX for outpatients with advanced /recurrent
gastric cancer is to be studied on the effectiveness and safety.
Safety,Efficacy
Confirmatory
Pragmatic
Phase I,II
Response rate
overall survival(OS),progression free survival, and Incidence of adverse events
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine |
Treatment Methd
CDDP 30mg/m2:day 1, day15,
PTX 70mg/m2:day 1, day15,
TS-1 80/mgm2:day1 – 21(on), day22 – 35(off)
A 5 weeks is the one course
20 | years-old | <= |
75 | years-old | >= |
Male and Female
(1) diagnosed histologicaly and/or cytologicaly
(2) with measurable lesions
(3) without any prior therapy except patients who have received other Chemotherapies than CDDP, PTX or TS-1 before 4 weeks of this Study
(4) with normal organ functions
1) Hb <= 8.0g/dL
2) WBC:4,000-12000/mm3
3) Neutro: <=2000/mm3
4) Platelet: <=10x104/mm3
5) T.bil: >=1.5mg/dL
6) AST/ALT: <100 IU/L or <150 IU/L in patients with liver
Metastasis
7) sCr <= 1.2mg/dL1.
8) CCr >= 60mL/min in Cockcroft-Gault method
(5) PS 0-2
(6) longer than 3 months of the expected survival period
(7) age between 20 and 75 years old
(8) patients who can take orally
(9) with written informed consent
(1) with bleeding from digestive tract
(2) patients who cannot take orally due to some stenosis on digestive tract
(3) past history of severe allergy against some medicines
(4) with high volume of ascites and/or thoratic fluid
(5) with severe diseases (infection, interstitial pneumonitis, pulmonary fibrosis, cardiac failure, renal failure, liver disease, uncontrollable DM)
(6) with liver cirrhosis and/or jaundice
(7) with psychologic disorder which needs medicines
(8) with brain disorder due to brain metastasis
(9) with active second cancers.
(10) women under pregnancy or women expecting future birth
(11) doctors decision not to register to this trial
40
1st name | |
Middle name | |
Last name | Kimura Yutaka |
NTT West Japan Hospital
Dpt.Surgery
543-8922 2-6-40Karasugatuji Tennnouji-Ku Osaka
06-6773-7111
1st name | |
Middle name | |
Last name | Hiroshi Furukawa |
Kinki University Faculty of Medicen
Department of surgery
377-2, Onohigashi, Osakasayama, Osaka, Japan
072-366-0221
OGSG
NPO Osaka Chinical Study Supporting Organization
Self funding
NO
2009 | Year | 07 | Month | 10 | Day |
Unpublished
Completed
2009 | Year | 05 | Month | 13 | Day |
2009 | Year | 05 | Month | 01 | Day |
2012 | Year | 05 | Month | 21 | Day |
2012 | Year | 12 | Month | 01 | Day |
2012 | Year | 11 | Month | 01 | Day |
2009 | Year | 07 | Month | 10 | Day |
2013 | Year | 01 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002679
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |